Accuray Incorporated CFO to Present at 7th Annual Needham & Company Biotechnology...

Accuray Incorporated CFO to Present at 7th Annual Needham & Company
Biotechnology & Medical Technology Conference

SUNNYVALE, Calif., June 6 /PRNewswire-FirstCall/ -- Accuray Incorporated
(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today
that its senior vice president and chief financial officer, Robert E. McNamara
is scheduled to present at the 7th Annual Needham & Company Biotechnology &
Medical Technology Conference at the New York Palace Hotel in New York City on
Wednesday, June 11, 2008 at 9:30 a.m. EDT (6:30 a.m. PDT).
A live webcast of the presentation will be available online from the
investor relations page of the Company's Web site at http://www.accuray.com.
The webcast replay of the presentation will begin approximately 30 minutes
after the conclusion of the live presentation and will be available for
approximately 30 days.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body stabilization
frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to treat more than 40,000 patients
worldwide and currently more than 130 systems have been installed in leading
hospitals in the Americas, Europe and Asia. For more information, please visit
http://www.accuray.com.
SOURCE Accuray Incorporated

Investors, Tom Rathjen, Vice President, Investor Relations, +1-408-789-4458,
trathjen@accuray.com, or Media, Stephanie Tomei, Public Relations Manager,
+1-408-789-4234, stomei@accuray.com, both of Accuray Incorporated